Alnylam Pharmaceuticals Inc (ALNY)
Here's Why Alnylam Pharmaceuticals (ALNY) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Best Momentum Stocks to Buy for January 21st
CDNA, AVXL and ALNY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 21, 2025.
Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year?
Here is how Alnylam Pharmaceuticals (ALNY) and Medpace (MEDP) have performed compared to their sector so far this year.
ALNY Announces Preliminary 2024 Results, 2025 View & Pipeline Goals
Alnylam reports preliminary fourth-quarter and full-year 2024 product revenues. The company expects to deliver adjusted operating income profitability in 2025.
Alnylam Pharmaceuticals: Commercialization And Early-Stage Studies Are Likely To Drive 2025
Alnylam Pharmaceuticals: Commercialization And Early-Stage Studies Are Likely To Drive 2025
Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?
Here is how Alnylam Pharmaceuticals (ALNY) and argenex SE (ARGX) have performed compared to their sector so far this year.
What Makes Alnylam (ALNY) a New Buy Stock
Alnylam (ALNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use
ALNY reports submitting an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.
ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study
Alnylam shares interim phase I amyloidosis study data on nucresiran, showing rapid TTR reduction sustained for six months after a single dose.
Alnylam downgraded to Underperform from Peer Perform at Wolfe Research
Wolfe Research downgraded Alnylam to Underperform from Peer Perform, citing "unfriendly channel dynamics coupled with inability to rebate."
Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down
ALNY's Q3 loss per share matches the Zacks Consensus Estimate and revenues miss the same due to lower collaboration revenues. The stock falls 5.3%.
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2024 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2024 Earnings Call Transcript
